已收盤 11-20 16:00:00 美东时间
+0.043
+4.57%
今日重点评级关注:HC Wainwright & Co.:维持Cerenome"买入"评级,目标价从1美元升至7美元;HC Wainwright & Co.:维持Greenwich LifeSciences"买入"评级,目标价从69美元升至70美元
11-19 19:40
Oppenheimer analyst Jay Olson maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform and lowers the price target from $10 to $9.
11-18 22:09
Tvardi Therapeutics (NASDAQ:TVRD) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 18.64 percent increase over losses of $(0.59) per share from the same period last year.
11-13 20:09
Tvardi Therapeutics reported Q3 2026 financial results and business updates. The company advanced its STAT3 inhibitor programs, including TTI-109 for ulcerative colitis and TTI-101 for hepatocellular carcinoma. Financials showed $4.5M R&D expenses and a net loss of $6.1M. Cash reserves of $22.3M are expected to fund operations into Q3 2027. Key milestones include initiating TTI-109 trials in UC and reporting TTI-101 HCC data in early 2027.
11-13 12:00
今日重点评级关注:BTIG:维持Rapport Therapeutics"买入"评级,目标价从75美元升至89美元;摩根士丹利:维持希捷科技"超配"评级,目标价从1187美元升至1200美元
10-21 12:30
Chardan Capital analyst Gautam Chukka initiates coverage on Tvardi Therapeutics (NASDAQ:TVRD) with a Buy rating and announces Price Target of $8.
10-20 19:56
In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and modulated STAT3-driven disease biology Collective findings now span multiple preclinical models of UC...
09-24 20:04
Tvardi Therapeutics announced the publication of preclinical data in *International Journal of Molecular Sciences* evaluating their STAT3 inhibitor TTI-101 in a chronic colitis model. The study demonstrated high colon exposure, normalization of STAT3-regulated gene expression, and prevention of colon polyps and adenocarcinomas. These findings support the potential of STAT3 inhibition in treating ulcerative colitis (UC) by targeting immune dysregu...
09-24 12:00
Kura Oncology launched Caspian Therapeutics, a separately financed subsidiary focused on developing small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian secured $50 million in financing led by BVF Partners, with participation from T1D Fund, Eli Lilly, and others. The company will advance KO-7246, a next-generation menin inhibitor, through clinical proof of concept. Preclinical studies demonstrate KO-7246's potential ...
09-09 11:00
Tvardi Therapeutics announced its participation in upcoming investor events: the Wells Fargo 21st Annual Healthcare Conference on September 9 in Boston, the 2026 Cantor Global Healthcare Conference on September 10 in New York, and the H.C. Wainwright 28th Annual Global Investment Conference on September 14 in New York. The company focuses on developing oral STAT3 inhibitors for inflammatory and proliferative diseases. TTI-109, a prodrug of TTI-10...
08-26 12:00